Outcome of active anti‐cancer treatment in elderly patients with advanced non‐small cell lung cancer: A single center experience. Issue 2 (March 2014)

• Record Type: Journal Article
• Authors: Kim, Ji Hye; Ryu, Min Sun; Ryu, Yon Ju; Lee, Jin Hwa; Shim, Sung Shine; Kim, Yookyung; Chang, Jung Hyun
• Is Part Of: Thoracic cancer. Volume 5:Issue 2(2014)
• Page Start: 133
• Page End: 138
• Publication Date: 2014-03
• Subjects: Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.12066
• Languages: English
• ISSNs: 1759-7706

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="tca12066-sec-0001" sec-type="section"> <title>Background</title> <p>This study aimed to evaluate the characteristics of active anti‐cancer treatment (AAT) compared with best supportive care (BSC) in elderly patients with advanced non‐small cell lung cancer (NSCLC).</p> </sec> <sec id="tca12066-sec-0002" sec-type="section"> <title>Methods</title> <p>A retrospective analysis of 144 patients, aged 70 or older, with stage IIIb/IV NSCLC from 672 patients with confirmed lung cancer, was conducted.</p> </sec> <sec id="tca12066-sec-0003" sec-type="section"> <title>Results</title> <p>Median age at diagnosis was 77 years and median survival time was five months. On multivariate analysis, AAT independently contributed to a decreased hazard ratio of death (P = 0.04), whereas male gender (P = 0.004), a body mass index of less than 18.5 (P = 0.004), and a poor performance score were associated with an increased risk of death (P < 0.001). The 52 subjects receiving AAT experienced longer survival than the 92 subjects receiving BSC (median seven months [AAT] versus three months [BSC]; P < 0.001). When sub‐classified into five‐year age intervals, AAT was a significant advantage in overall survival (OS) to patients aged 70–74, but not to those ≥75 years old.</p> </sec> <sec id="tca12066-sec-0004" sec-type="section"> <title>Conclusions</title> <p>AAT for patients ≥70 years old with advanced NSCLC extended OS. However, care should be taken in decisions on active anti‐cancer treatments for patients over 75 years old. A prospective multicenter trial is required in the near future.</p> </sec> </abstract>